CAS 1402936-61-1

Runcaciguat

CAS : 1402936-61-1

Runcaciguat

Degré de pureté : ≥98%

Masse moléculaire : 488.33g/mol

Ref: 54-BUP05048

Runcaciguat

CAS : 1402936-61-1

Formule : C₂₃H₂₂Cl₂F₃NO₃

Masse moléculaire : 488.33

Ref: 4Z-R-175001

Runcaciguat

CAS : 1402936-61-1

Runcaciguat is a compound that inhibits the mineralocorticoid receptor. Runcaciguat has been shown to improve symptoms of chronic kidney disease and reduces the incidence of cancer in patients with chronic kidney disease. This drug also inhibits the activity of serine proteases, which are enzymes that break down proteins. Runcaciguat has been shown to inhibit soluble guanylate cyclase, which is an enzyme that converts GTP into cGMP, causing a decrease in cGMP levels and subsequent relaxation of blood vessels. This can help increase renal blood flow in patients with metabolic disorders or endometriosis. Clinical studies have indicated that runcaciguat may be effective in treating cardiac diseases such as hypertension and congestive heart failure (CHF).

Formule : C₂₃H₂₂Cl₂F₃NO₃

Degré de pureté : Min. 95%

Masse moléculaire : 488.3 g/mol

Ref: 3D-CGC93661

Runcaciguat

CAS : 1402936-61-1

Runcaciguat, a soluble guanylate cyclase stimulator, aids in cardiovascular and renal research.

Formule : C₂₃H₂₂Cl₂F₃NO₃

Degré de pureté : 99.17%

Couleur et forme : Solid

Masse moléculaire : 488.33

Ref: TM-T16808